Baird Maintains Outperform on Karyopharm Therapeutics, Lowers Price Target to $5
Portfolio Pulse from Benzinga Newsdesk
Baird analyst Mitch Collett maintains an Outperform rating on Karyopharm Therapeutics (NASDAQ:KPTI) but lowers the price target from $8 to $5.
August 07, 2024 | 3:49 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Baird analyst Mitch Collett maintains an Outperform rating on Karyopharm Therapeutics but lowers the price target from $8 to $5.
The Outperform rating suggests a positive outlook, but the lowered price target indicates tempered expectations. This mixed signal may result in neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100